Abstract
Introduction

Insulin autoimmune syndrome (IAS) was first reported in 1970 by Hirata et al (1). This syndrome is a condition characterized by frequent hypoglycemic attacks associated with the presence of autoantibodies to insulin in patients who have not received insulin injections. More than 200 IAS patients have been reported in Japan where it represents the third leading cause of spontaneous hypoglycemia
; only 27 cases have been described from outside Asia. Forty-one percent of Japanese patients with IAS had other autoimmune diseases such as Graves' disease and rheumatoid arthritis. A strong association between IAS and HLA DR4 has been shown in 96% of Japanese patients (HLA DR4 frequency is 43% in normal Japanese controls) (2) (4, 5) . In most cases, insulin autoantibodies appear a few weeks after the beginning of treatment with a drug containing the sulphydryl group (5, 6) t u r e p r o d u c e s t h e s t r o n g r e d u c t i v e e f f e c (13) . A relatively high frequency of HLA DRB1* 0406 (3.22%) in Japanese was described (14) . Given that ALA has come to be widely used as a health supplement, it will be important to be more careful to watch for the development of IAS connected with ALA.
I -I RI ) d u r i n g t h e f o l l o w-u p o f t h i s p a t i e n t .
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